Irish reimbursement granted for AbbVie's RINVOQ® (upadacitinib)

AbbVie has announced the availability in Ireland of upadacitinib, an oral, selective and reversible Janus Kinase (JAK) inhibitor, for the treatment of

Related Keywords

Ireland ,Dublin ,Irish ,Alan Irvine ,Andres Rodrigo ,Management Programme ,European Commission ,Trinity College Dublin ,Janus Kinase ,Medicines Management Programme ,Managed Access ,Eczema Area ,Severity Index ,Global Assessment ,Atopic Dermatitis ,Irish General Manager Andres Rodrigo ,